Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer

Inclusion Criteria: * • Age between 18 and 75 years (inclusive). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed, KRAS-mutated, unresectable metastatic pancreatic ductal adenocarcinoma (PDAC). * Documented disease progression after at least one prior line of systemic therapy. * Estimated life expectancy of ≥ 12 weeks. * At least one measurable objective tumor lesion according to RECIST v1.1. The maximum diameter must be ≥ 1 cm by spiral CT, or ≥ 2 cm by standard CT or MRI; imaging must be performed within 28 days prior to enrollment. * Adequate bone marrow and organ function, defined as follows (without the use of hematopoietic growth factors or blood transfusions within 7 days prior to testing): * Hematology: Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count ≥ 75 × 10\^9/L, and hemoglobin ≥ 90 g/L. * Hepatic: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. * Renal: Creatinine clearance ≥ 60 mL/min (calculated using the Cockcroft-Gault formula). * Coagulation: International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN. * Cardiac: Normal electrocardiogram (ECG) or abnormal ECG deemed clinically insignificant by the investigator. * Urinalysis: Urine protein \< 2+; if urine protein is ≥ 2+, a 24-hour urine protein quantification must be \< 1.0 g. * Participants of childbearin…